Upregulated expression of serum exosomal miR-375 and miR-1307 enhance the diagnostic power of CA125 for ovarian cancer

被引:79
|
作者
Su, Ying Ying [1 ]
Sun, Li [1 ]
Guo, Zhi Rui [1 ]
Li, Jin Chang [2 ]
Bai, Ting Ting [1 ]
Cai, Xiao Xiao [1 ]
Li, Wen Han [1 ]
Zhu, Ye Fei [1 ]
机构
[1] Nanjing Med Univ, Affiliated Hosp 2, Nanjing 210011, Jiangsu, Peoples R China
[2] Nanjing Univ Chinese Med, Jiangsu Prov Hosp Tradit Chinese Med, Affiliated Hosp, Nanjing, Jiangsu, Peoples R China
关键词
Ovarian cancer; Serum exosome; microRNA; Biomarker; BREAST-CANCER; TUMOR-MARKER; PROGNOSIS; WOMEN; COMMUNICATION; MICRORNA-375; COMBINATION; STATISTICS; CA-125; TOOLS;
D O I
10.1186/s13048-018-0477-x
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
BackgroundOvarian cancer (OC) is associated with high mortality in gynecological oncology; this is mainly due to the low diagnosis rate. Exosomal miRNA has demonstrated potential as a tumor biomarker. We aimed to explore the diagnostic potential of serum exosomal miR-1307 and miR-375 forOC.MethodsThe first six candidate miRNAs were selected from the previous literature. The relative quantification of qRT-PCR was used to screen for the stability of exosomal miRNAs, followed by validation of the cohort. ROC analysis was employed to analyze the specificity and sensitivity of exosomal miRNA.ResultsMiR-1307 and miR-375 were confirmed stably existing in serum exosomes of OC. Moreover, miR-1307 and miR-375 were both significantly up-regulated in serum exosomes of OC compared to ovarian benign and healthy groups. The overexpressed miRNAs showed independent diagnostic power and enhanced the diagnostic accuracy of traditional biomarkers when combined with CA-125 and HE4. MiR-1307 was associated with tumor staging, and miR-375 was associated with lymph node metastasis of OC.ConclusionOur results suggest that serum exosomal miR-1307 and miR-375 could serve as potential tumor biomarkers to improve diagnostic efficiency for OC.
引用
收藏
页数:9
相关论文
共 44 条
  • [41] RETRACTED: A Clinical Diagnostic Value Analysis of Serum CA125, CA199, and HE4 in Women with Early Ovarian Cancer: Systematic Review and Meta-Analysis (Retracted Article)
    Qing, Xiaolin
    Liu, Liting
    Mao, Xiguang
    COMPUTATIONAL AND MATHEMATICAL METHODS IN MEDICINE, 2022, 2022
  • [42] Vascular endothelial growth factor expression correlates with serum CA125 and represents a useful tool in prediction of refractoriness to platinum-based chemotherapy and ascites formation in epithelial ovarian cancer
    Masoumi-Moghaddam, Samar
    Amini, Afshin
    Wei, Ai-Qun
    Robertson, Gregory
    Morris, David L.
    ONCOTARGET, 2015, 6 (29) : 28491 - 28501
  • [43] Can circulating PD-1, PD-L1, pan-BTN3As, BTN3A1, BTN2A1 and BTLA levels enhance prognostic power of serum CA125 in patients with advanced high-grade serous ovarian cancer?
    Corsini, L. R.
    Fanale, D.
    Brando, C.
    Cutaia, S.
    Di Donna, M. C.
    Randazzo, U.
    Magrin, L.
    Filorizzo, C.
    Gurrera, V.
    Fiorino, A.
    Pedone, E.
    Di Piazza, M.
    Dimino, A.
    Scalia, R.
    Romano, R.
    Russo, T. D. Bazan
    Chiantera, V.
    Russo, A.
    Bazan, V.
    Iovanna, J. L.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S593 - S594
  • [44] Can circulating PD-1, PD-L1, BTN3A1, pan-BTN3As, BTN2A1 and BTLA levels enhance prognostic power of CA125 in patients with advanced high-grade serous ovarian cancer?
    Fanale, Daniele
    Corsini, Lidia Rita
    Brando, Chiara
    Cutaia, Sofia
    Di Donna, Mariano Catello
    Filorizzo, Clarissa
    Lisanti, Maria Chiara
    Randazzo, Ugo
    Magrin, Luigi
    Romano, Raffaella
    Russo, Tancredi Didier Bazan
    Olive, Daniel
    Vieni, Salvatore
    Pantuso, Gianni
    Chiantera, Vito
    Russo, Antonio
    Bazan, Viviana
    Iovanna, Juan Lucio
    FRONTIERS IN ONCOLOGY, 2022, 12